


## Rofecoxib

## Chemical Properties

CAS No. :	162011-90-7
Formula:	C <sub>17</sub> H <sub>14</sub> O <sub>4</sub> S
Molecular Weight:	314.36
Appearance:	no data available
Storage:	Powder: -20°C for 3 years   In solvent: -80°C for 1 year



## Biological Description

Description	Rofecoxib (MK 966) binds to and inhibits the enzyme cyclooxygenase-2 (COX-2), resulting in an inhibition of the conversion of arachidonic acid to prostaglandins. Rofecoxib is a synthetic, nonsteroidal derivative of phenyl-furanone with anti-inflammatory, antipyretic and analgesic properties and potential antineoplastic properties. COX-related metabolic pathways may represent key regulators of cell proliferation and neo-angiogenesis. Some epithelial tumor cell types overexpress pro-angiogenic COX-2.
Targets(IC50)	COX
In vitro	Rofecoxib inhibits the COX-2-dependent production of PGE <sub>2</sub> in human osteosarcoma cells with an IC <sub>50</sub> of 26 nM. Rofecoxib is a time-dependent inhibitor of purified human recombinant COX-2 with an IC <sub>50</sub> of 0.34 μM. Rofecoxib causes inhibition of purified human COX-1 in a non-time-dependent manner. In a human whole blood assay, Rofecoxib selectively inhibits lipopolysaccharide-induced, COX-2-derived PGE <sub>2</sub> synthesis with an IC <sub>50</sub> value of 0.53 μM compared with an IC <sub>50</sub> value of 18.8 μM for the inhibition of COX-1-derived thromboxane B <sub>2</sub> synthesis after blood coagulation. [1] Rofecoxib moderately inhibits phenacetin O-deethylation with an IC <sub>50</sub> of 23 μM. And a 30-minute preincubation with microsomes and NADPH considerably increases the inhibitory effect of Rofecoxib with an IC <sub>50</sub> of 4.2 μM. Inactivation of CYP1A2 by rofecoxib requires NADPH, and is characterized by a K <sub>i</sub> of 4.8 μM. [2]
In vivo	Rofecoxib potently inhibits carrageenan-induced paw edema, carrageenan-induced paw hyperalgesia, and lipopolysaccharide-induced pyresis with IC <sub>50</sub> values of 1.5 mg/kg, 1.0 mg/kg, and 0.24 mg/kg, respectively. It also blocks adjuvant-induced arthritis (IC <sub>50</sub> = 0.74 mg/kg/day) and protects cartilage and bone in rats. [1] Oral administration decreases portal pressure in CCl <sub>4</sub> -treated rats, reduces activated HSCs, and downregulates hepatic levels of collagen, laminin, VEGF, and CTGF. [3]
Kinase Assay	In vitro biochemical and pharmacological assaysinhibition studies with recombinant human COX-1 and COX-2: Microsomal preparations of recombinant human COX-1 and COX-2 are prepared from a vaccinia virus-COS-7 cell expression system. Recombinant human COX-1 and COX-2 are expressed in baculovirus-Sf9 cells, and enzymes are purified. Enzymatic activity is monitored continuously by either a fluorescence assay measuring the appearance of the oxidized form of the reducing agent cosubstrate homovanillic acid or by oxygen consumption. The HPLC assay for the assessment of inhibition of purified COX-1 by Rofecoxib with 0.1 μM arachidonic acid substrate

concentration, the determination of the stoichiometry of the complex between COX-2 and Rofecoxib, the dissociation rate constant of the enzyme-inhibitor complex by recovery of enzymatic activity, and the recovery of intact Rofecoxib from that complex are all performed as described previously. The solvent system for the HPLC analysis of Rofecoxib is 15:85 MeOH/aqueous potassium phosphate (1 g/liter), with elution by a linear gradient of 15 to 75% MeOH over 25 minutes with detection at 275 nm on a Novapak C18 column.

## Cell Research

The human osteosarcoma cell line has been shown to selectively express COX-2 by reverse transcription-polymerase chain reaction and immunoblot analysis, whereas undifferentiated human lymphoma U937 cells selectively express COX-1. The production of PGE2 by these cells after arachidonic acid challenge is used as an index of cellular COX-2 and COX-1 activity, respectively. Rofecoxib is preincubated for 5 to 15 minutes with the cells under serum-free conditions [Hanks' balanced salt solution (HBSS)] before a 10-minutes stimulation with 10  $\mu$ M arachidonic acid and measurement of PGE2 production. COX activity in each cell line is defined as the difference in PGE2 concentrations in samples incubated in the presence or absence of arachidonic acid. (Only for Reference)

## Solubility Information

## Solubility

DMSO: 50 mg/mL (159.05 mM), Sonication is recommended.  
Ethanol: < 1 mg/mL (insoluble or slightly soluble),  
H2O: < 1 mg/mL (insoluble or slightly soluble),  
(< 1 mg/ml refers to the product slightly soluble or insoluble)

## Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	3.1811 mL	15.9053 mL	31.8107 mL
5 mM	0.6362 mL	3.1811 mL	6.3621 mL
10 mM	0.3181 mL	1.5905 mL	3.1811 mL
50 mM	0.0636 mL	0.3181 mL	0.6362 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

## Reference

- Chan CC, et al. J Pharmacol Exp Ther. 1999, 290(2), 551-560.  
Karjalainen MJ, et al. Drug Metab Dispos. 2006, 34(12), 2091-2096.  
Tu CT, et al. J Gastroenterol Hepatol. 2007, 22(6), 877-884.

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

**This product is for Research Use Only. Not for Human or Veterinary or Therapeutic Use**

Tel: 781-999-4286 E\_mail: info@targetmol.com Address: 36 Washington Street, Wellesley Hills, MA 02481